{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:36:29Z","timestamp":1769164589284,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anales de Pediatr\u00eda"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.anpedi.2019.09.008","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T14:22:13Z","timestamp":1573222933000},"page":"415.e1-415.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nuevos f\u00e1rmacos antiepil\u00e9pticos en Pediatr\u00eda"],"prefix":"10.1016","volume":"91","author":[{"given":"Ignacio","family":"M\u00e1laga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"S\u00e1nchez-Carpintero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Rold\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Ramos-Lizana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"Garc\u00eda-Pe\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anpedi.2019.09.008_bib0185","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1528-1167.2009.02481.x","article-title":"Estimation of the burden of active and life-time epilepsy: a meta-analytic approach","volume":"51","author":"Nguki","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0190","first-page":"36","article-title":"Childhood epilepsy: an update on diagnosis and management","volume":"5","author":"Saad","year":"2014","journal-title":"Am J Neurosc"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0195","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(06)68182-8","article-title":"Epilepsy in children","volume":"367","author":"Guerrini","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0200","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ensci.2016.06.003","article-title":"Antiepileptic drugs in development pipeline: a recent update","volume":"4","author":"Kaur","year":"2016","journal-title":"EneurologicalSci"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0205","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejpn.2013.02.003","article-title":"Advancing the management of childhood epilepsies","volume":"17","author":"Cross","year":"2013","journal-title":"Eur J Pediatr Neurol"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0210","doi-asserted-by":"crossref","first-page":"s4","DOI":"10.1177\/08830738020170010201","article-title":"Update on the epidemiology and prognosis of pediatric epilepsy","volume":"17","author":"Shinnar","year":"2002","journal-title":"J Child Neurol"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0215","series-title":"Pediatric Epilepsy Diagnosis and Treatment. Third ed.","first-page":"147","article-title":"Epidemiology of epilepsy in children","author":"Hauser","year":"2008"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0220","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0074-7742(06)81006-8","article-title":"Mechanisms of action of antiepileptic drugs","volume":"81","author":"White","year":"2007","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0225","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0163-7258(01)00122-X","article-title":"The mechainsms of action of commonly used antiepileptic drugs","volume":"90","author":"Kwan","year":"2001","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0230","first-page":"508","volume":"25","author":"Abbou-Khalil","year":"2019","journal-title":"Update on antiepileptic drugs 2019. Continuum (Minneap Minn)"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0235","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/14740338.2018.1518427","article-title":"Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy","volume":"17","author":"Moavero","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0240","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pediatrneurol.2017.05.016","article-title":"Trends in antiepileptic drug use in children and adolescents with epilepsy","volume":"74","author":"Liu","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0245","first-page":"249","volume":"20","author":"Arzimanoglou","year":"2018","journal-title":"for PEACE. A review of the new antiepileptic drugs for focal-onset seizures in pediatrics: role of extrapolation. Pediatr Drugs"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0250","unstructured":"International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guidline. Addendum to ICH E11: Clinical Investigation of Medicinal Products in the Pediatric Population. 2016. [consultado 1 Sep 2019]. Disponible en:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E11\/E11R1EWG_Step4_Addendum_2017_0818.pdf."},{"key":"10.1016\/j.anpedi.2019.09.008_bib0255","unstructured":"European Medical Agency. Reflection paper on extrapolation of efficacy and safety in paediatric medicine development\u2014Draft. [consultado 1 Sep 2019]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_.procedural_guideline\/2016\/04\/WC500204187.pdf."},{"key":"10.1016\/j.anpedi.2019.09.008_bib0260","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","article-title":"Pharmacokinetics and drug interactions of eslicarbazepine acetate","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yebeh.2018.01.029","article-title":"Effects of adjuntive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures","volume":"81","author":"J\u00f3zwiak","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0270","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2014.11.021","article-title":"Current understanding of the mechanism of action of the antiepileptic drug lacosamide","volume":"11","author":"Rogawski","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0275","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.seizure.2018.01.014","article-title":"Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic review","volume":"56","author":"Ortiz de la Rosa","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0280","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.yebeh.2014.09.074","article-title":"Safety and efficacy of adjunctive lacosamide among patients with partial onset seizures in a long-term open-label extension trial up to 8 years","volume":"41","author":"Rosenfeld","year":"2014","journal-title":"Epilespy Behav"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0285","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.pediatrneurol.2013.06.005","article-title":"Ring chromosome 20: a pediatric potassium channelopathy responsive to treatment with ezogabine","volume":"49","author":"Walleigh","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0290","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13052-017-0368-6","article-title":"Current role of perampanel in pediatric epilepsy","volume":"43","author":"De Liso","year":"2017","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0295","first-page":"188","article-title":"Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: the first real-world evaluation in Asian pediatric neurology clinics","volume":"85","author":"Kuang-lin","year":"2018","journal-title":"Epilepsy&Behavior"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0300","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","article-title":"The natural history of epilepsy in tuberous sclerosis complex","volume":"51","author":"Chu-Shore","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0305","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0310","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0315","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjuntive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomized, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0320","article-title":"Brivaracetam: a novel antiepileptic drug for focal-onset seizures","volume":"11","author":"Stephen","year":"2017","journal-title":"Ther Adv Neruol Disord"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0325","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40272-019-00332-y","article-title":"Safety and tolerability of adjunctive brivaracetam in pediatric patients < 16 years with epilepsy: an open-label trial","volume":"21","author":"Liu","year":"2019","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0330","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0335","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","article-title":"Molecular targets of cannabidiol in neurological disorders","volume":"12","author":"Ibeas Bith","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0340","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0345","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patienst with seizures associated with lennox Gastaut syndrome (GWPCARE4): a randomized, double-bling, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0350","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Canabidiol in patients with treatment-resistant epilepsy; an open-label intervetional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0355","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1535759719835671","article-title":"Don\u2019t fear the refeer- Evidence mounts for plant-based cannabidiol as treatment for epilepsy","volume":"19","author":"Scott Perry","year":"2019","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.anpedi.2019.09.008_bib0360","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eplepsyres.2017.11.008","article-title":"Indirect comparison of third-generation antiepileptic drugs as adjunctive treatment for uncontrolled focal epilepsy","volume":"139","author":"Li-Na","year":"2018","journal-title":"Epilepsy Res"}],"container-title":["Anales de Pediatr\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1695403319302875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1695403319302875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:49:35Z","timestamp":1761662975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1695403319302875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1695403319302875"],"URL":"https:\/\/doi.org\/10.1016\/j.anpedi.2019.09.008","relation":{},"ISSN":["1695-4033"],"issn-type":[{"value":"1695-4033","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nuevos f\u00e1rmacos antiepil\u00e9pticos en Pediatr\u00eda","name":"articletitle","label":"Article Title"},{"value":"Anales de Pediatr\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anpedi.2019.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}